- Home
- SPRO vs CNTY Comparison
SPRO vs CNTY Comparison
Compare SPRO & CNTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRO | CNTY |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 45.1M |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SPRO | CNTY |
|---|---|---|
| Price | $2.71 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 324.6K | 81.5K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 51.31 |
| EPS | ★ 0.15 | N/A |
| Revenue | $66,802,000.00 | ★ $430,529,000.00 |
| Revenue This Year | N/A | $7.17 |
| Revenue Next Year | $300.00 | $3.28 |
| P/E Ratio | $17.80 | ★ N/A |
| Revenue Growth | ★ 39.24 | 10.82 |
| 52 Week Low | $0.52 | $1.23 |
| 52 Week High | $3.09 | $2.85 |
Technical Indicators
Market Signals| Indicator | SPRO | CNTY |
|---|---|---|
| Relative Strength Index (RSI) | 67.76 | 55.55 |
| Support Level | $2.15 | $1.48 |
| Resistance Level | $3.09 | $1.56 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 93.52 | 83.33 |
Price Performance
Historical ComparisonAbout SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has three reportable segments based on the geographical locations in which its casinos operate; United States; Century Casino & Hotel-Central City, and Century Casino & Hotel-Cripple Creek in Colorado, Mountaineer Casino, Racetrack & Resort in West Virginia, and Century Casino Caruthersville, and Century Casino Cape Girardeau in Missouri, Canada; Century Casino & Hotel, Century Casino St. Albert, Century Mile Racetrack in Edmonton and Casino Century Downs Racetrack and Casino in Calgary, and Poland; Casinos Poland.